Bavarian and other RSV companies navigating uncharted territory

Despite the pharma industry's massive interest in Respiratory Syncytial Virus (RSV), companies still lack established means of evaluating the outcome of phase III trials in the indication. It puts pressure on front-runners like Bavarian Nordic and Reviral.

Photo: /Ritzau Scanpix/Asger Ladefoged

The respiratory illness RSV is a popular indication among pharma giants like Sanofi and Pfizer as well as smaller biotech firms in the US and Europe.

However, the interest is still so new that there is no current standards for how to measure the outcome of a vaccine or therapy in clinical phase III trials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Latest news

See all jobs